Berger Montague has filed a securities fraud class action lawsuit against Erasca, Inc. on behalf of investors who purchased or acquired Erasca common stock between January 14, 2025 and April 26, 2026. The suit alleges that the company misrepresented its lead drug candidate ERAS-0015 as a potential best-in-class therapy with superior preclinical results compared to Revolution Medicines' RMC-6236. On April 27, 2026, Erasca disclosed accusations of patent infringement and trade secret misappropriation from Revolution Medicines, and reported preliminary clinical data including a patient death while admitting its comparisons relied on cross-study analyses rather than head-to-head trials. Erasca's stock fell more than 45% on the news. Investors have until August 10, 2026 to seek appointment as lead plaintiff.
Erasca IncSecurities fraud class action lawsuit filed, alleging misrepresentation of lead drug candidate and patent infringement/trade secret misappropriation.
Revolution Medicines IncErasca's lead drug candidate compared unfavorably to Revolution Medicines' RMC-6236, and Erasca accused of patent infringement/trade secret misappropriation from Revolution Medicines.